It is very uncertain whether lamotrigine changes any reported adverse effects up to 12 weeks after starting treatment… compared with placebo (very low certainty).
Lamotrigine showed no clear difference in any reported adverse effects 6‐12 months after initiating the… compared with placebo (moderate certainty).
Comparison 7: Family therapy showed no clear difference in repetition of SH at post‐intervention compared with placebo (moderate certainty).
Antipsychotics may leads to lower repetition of SH by post‐intervention№ of participants: 30(1 RCT) compared with placebo (low certainty).
It is very uncertain whether mood stabilisers, including antiepileptics and lithium changes repetition of SH by post‐intervention№ of participants: 167(1 RCT) compared with placebo (very low certainty).
Natural products showed no clear difference in repetition of SH by post‐intervention№ of participants: 49(1 RCT) compared with placebo (low certainty).
Behavioural activation showed no clear difference in treatment acceptabilityup to 6 months (16 weeks) compared with placebo (low certainty).
Lithium leads to higher efficacy: response (categorical) YMRS/MRS decrease by ≥ 50% at end… compared with placebo (high certainty).
Lithium leads to higher efficacy: remission (categorical) YMRS < 12 at end of study compared with placebo (high certainty).
Lithium showed no clear difference in acceptability: total withdrawals compared with placebo (moderate certainty).
Lithium leads to higher adverse event: tremor compared with placebo (high certainty).
Lithium leads to higher adverse event: somnolence compared with placebo (high certainty).
Lithium showed no clear difference in adverse event: weight gain compared with placebo (moderate certainty).
Valproate leads to higher response rate at 3 weeks (primary efficacy outcome) compared with placebo (high certainty).
Valproate showed no clear difference in dropout rate ‐ All‐cause At 4‐6 weeks (secondary acceptability… compared with placebo (low certainty).
Valproate probably leads to higher number with any adverse event after 3 weeks (primary tolerability… compared with placebo (moderate certainty).
Valproate showed no clear difference in individual adverse events ‐ Sedation At 3‐8 weeks (secondary… compared with placebo (high certainty).